AbbVie Inc (ABBV)

Sep 28, 2026

ADARx Pharmaceuticals is seeking to raise up to $371.9 million in a U.S. IPO, targeting a valuation of up to $1.74 billion, with significant backing from AbbVie Inc. AbbVie has agreed to invest up to $100 million in a concurrent private placement, giving it a 4.9% stake, and previously collaborated with ADARx with a $335 million payment. While ADARx has multiple programs, including a late-stage candidate onvuzosiran, the IPO's success hinges on investors' willingness to value experimental medicines given the selective biotech IPO market.

Sep 28, 2026

Johnson & Johnson's oncology and immunology pipeline is poised to drive significant growth, despite challenges like the decline of its blockbuster drug STELARA and ongoing litigation costs. Analysts see a potential 15% upside for JNJ shares, with a target of $312, fueled by breakthroughs in treatments like CARVYKTI and TREMFYA. While the company faces a premium valuation compared to rivals, its diverse portfolio of 28 billion-dollar products and strategic initiatives are expected to ensure continued earnings growth.

Sep 28, 2026

AbbVie's new Parkinson's drug, Juvmo (tavapadon), has received FDA approval as the first selective D1/D5 receptor agonist for Parkinson's disease. Analyst Matt Phipps from William Blair projects Juvmo could generate $1.4 billion in sales by 2040, despite an anticipated slow initial launch due to gradual insurance coverage, with full Medicare access not expected until 2028. AbbVie views Juvmo, along with its other Parkinson's portfolio drugs, as a key long-term growth driver with potential peak sales of at least $5 billion.

Sep 28, 2026

AbbVie (NYSE:ABBV) has received FDA approval for JUVMO (tavapadon) tablets to treat adults with Parkinson's disease. The once-daily medication, which targets D1/D5 dopamine receptors, improved daily-living scores and increased "on" time in Phase 3 studies. AbbVie expects JUVMO to be available to U.S. patients in October 2026.

Sep 28, 2026

AbbVie Inc. has received FDA approval for its Parkinson's disease drug, Juvmo (tavapadon) tablets. This makes Juvmo the first and only selective D1/D5 receptor agonist approved for this indication, with its approval based on positive results from the Phase 3 TEMPO clinical development program. AbbVie plans to launch Juvmo in the U.S. in October.

Sep 28, 2026

AbbVie (ABBV) has received FDA approval for Juvmo (tavapadon), a new Parkinson’s disease treatment, expected to expand its neuroscience portfolio and future revenue. Despite this positive development, the company's high dividend payout ratio of 85% and its stock trading 19.5% above its GF Value™ raise concerns about dividend sustainability and valuation. AbbVie's GF Score™ of 78/100 indicates strong profitability but highlights weaknesses in financial strength and momentum, while mixed guru activity and insider selling further complicate the investment outlook.

Sep 28, 2026

The U.S. FDA has approved JUVMO (tavapadon) tablets by AbbVie for the treatment of adults with Parkinson's disease. JUVMO is the first and only selective D1/D5 receptor agonist for this condition, offering a new approach to motor symptom control. Its approval is supported by Phase 3 TEMPO program data, which showed significant improvements in daily functioning and increased "on" time without troublesome dyskinesia.

Sep 28, 2026

The FDA has approved Juvmo (tavapadon), AbbVie's new once-daily pill for Parkinson's disease, offering an additional treatment option for adults. Clinical trials showed common side effects including nausea, dizziness, and headache, and while it treats symptoms, it does not slow the disease progression. Juvmo acts as a dopamine agonist targeting D1 and D5 receptors, aiming to provide movement benefits with fewer side effects compared to older agonists.

Sep 27, 2026

Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia, is preparing to go public on the Nasdaq under the ticker IAM, aiming to raise up to $100 million. The company uses AI models to accelerate drug development, with its lead drug, IAM1363, already showing promising results in early-stage cancer trials. While the investment carries high risk as a clinical-stage biotech, Iambic's platform and partnerships offer a credible way to invest in AI-driven drug discovery.

Sep 25, 2026

This article compares the investment outlooks of AbbVie and Pfizer, detailing their financial performance, profitability, risks, and valuation. While AbbVie shows strong revenue growth in immunology, it faces patent expiration risks. Pfizer, despite a slight revenue decline, maintains higher profitability in vaccines and oncology and appears undervalued based on its forward P/E ratio.

Sep 25, 2026

The U.S. Food and Drug Administration has approved AbbVie's new drug, tavapadon (brand name Juvmo), for Parkinson's disease in adults. This once-a-day pill aims to help manage the long-term brain condition that affects movement control. AbbVie acquired the rights to tavapadon through its 2023 acquisition of Cerevel Therapeutics.

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.

Sep 25, 2026

ADARx Pharmaceuticals, a gene silencing biotech company, has successfully debuted on the public markets with an upsized IPO raising $446.3 million, and an additional $89 million through a private placement with AbbVie, totaling $535.3 million. The company's lead program, onvuzosiran, is in Phase 3 testing for hereditary angioedema, with a broader RNA therapies pipeline addressing immunological disorders, cardiovascular diseases, obesity, and neurodegeneration. ADARx's technology aims to overcome limitations of traditional therapies by enabling siRNA delivery beyond the liver and improving dosing frequency, with capital secured to advance its clinical pipeline into 2030.

Sep 25, 2026

REGENXBIO Inc. reported new three-year follow-up data from its ALTITUDE trial, showing that six out of ten higher-dose participants experienced a significant improvement in diabetic retinopathy severity. This data supports the ongoing Phase IIb/III NAAVIGATE trial, which is testing the gene therapy sura-vec against a sham control. The company expects topline results from its ATMOSPHERE and ASCENT trials for wet age-related macular degeneration in Q4 2026 and projects a cash runway into Q4 2027.

Sep 25, 2026

This article compares two dividend aristocrats, AbbVie (ABBV) and Johnson & Johnson (JNJ), to determine which is a better investment over the next decade, particularly for retirees. While AbbVie offers higher growth and a cheaper multiple, Johnson & Johnson is presented as the more stable choice due to its diversified revenue streams, strong balance sheet, and lower risk profile, especially for those dependent on dividend income. AbbVie faces patent cliffs and a leveraged balance sheet, making J&J a more secure option for income-focused investors.

Sep 25, 2026

ADARx Pharmaceuticals successfully raised $446 million in an upsized IPO, selling 26.3 million shares at $17 each. AbbVie also invested up to $100 million in a concurrent private placement, acquiring a 4.9% stake. The San Diego-based company, founded in 2019, specializes in RNA interference therapies for various conditions, with its lead candidate, Onvuzosiran, in late-stage trials for hereditary angioedema.

Sep 25, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month target price of $21.00. Despite recent financial results falling short of expectations, institutional investors maintain high ownership, holding nearly 95% of ENTA shares. The company's stock recently opened at $12.00, having a market cap of $349.50 million.

Sep 25, 2026

ADARx Pharmaceuticals, a late-stage clinical biotechnology company, announced the pricing of its upsized initial public offering, selling 26,250,000 shares of common stock at $17.00 per share, aiming to raise approximately $446.3 million. The shares are expected to begin trading on Nasdaq under "ADRX" on September 25, 2026. Additionally, AbbVie has agreed to purchase shares in a concurrent private placement, bringing the total expected gross proceeds to about $535.2 million.

Sep 24, 2026

This article compares Pfizer (PFE) and AbbVie (ABBV), two major U.S. drugmakers, to determine which stock offers a more attractive opportunity for investors. It delves into their fundamental business mixes, R&D pipelines, financial profiles, and valuation metrics. While Pfizer is diversifying its portfolio beyond COVID-19 products and building its oncology and obesity pipelines, AbbVie has successfully navigated the loss of exclusivity for Humira with its new immunology drugs, Skyrizi and Rinvoq, and is bolstering its pipeline through acquisitions.

Sep 24, 2026

Health Canada has issued a Notice of Compliance for AbbVie's drug EPKINLY (epcorit) for the treatment of follicular lymphoma. This announcement was made by AbbVie on Thursday, September 24, 2026. The article is a brief news update from MT Newswires.

Sep 23, 2026

Iambic Therapeutics, an AI drug discovery startup backed by Nvidia and Qatar Investment Authority, has filed for a U.S. IPO and simultaneously announced a multi-year research collaboration with AbbVie. The partnership involves AbbVie making an upfront payment of $40 million and potential milestone payments of up to $670 million, allowing it to leverage Iambic's AI platform for drug design in immunology, neuroscience, and oncology. This development highlights how AI models could accelerate pharmaceutical R&D, benefiting both the drug company seeking new molecules and the chip supplier expanding the ecosystem for its hardware and software.

Sep 23, 2026

AbbVie has changed its focus during earnings calls, no longer highlighting growth rates excluding Humira as that drug's sales decline has become less critical. The company now emphasizes the strong performance of Skyrizi and Rinvoq, which together account for a significant portion of its revenue. While this shift reflects an evolving portfolio, investors should monitor the continued growth rates of these key drugs and regulatory approvals to assess the company's long-term stability.

Sep 23, 2026

MindWalk (HYFT) is transitioning its business model towards recurring AI revenue with the commercial launch of its ReefIQ data platform. Despite a 21.3% revenue increase and 47.1% gross profit growth in Q1 FY27, the company saw widening operating losses and negative adjusted EBITDA due to commercial infrastructure spending for ReefIQ. MindWalk secured a US$30 million credit facility to support its growth strategy without shareholder dilution, although its profitability metrics remain a concern.

Sep 23, 2026

Iambic Therapeutics, an AI drug discovery startup backed by Nvidia and the Qatar Investment Authority, has filed for a U.S. IPO and simultaneously announced a multi-year research collaboration with AbbVie Inc. AbbVie will use Iambic's AI platform for small-molecule programs across immunology, neuroscience, and oncology, with an upfront payment and potential milestones. Nvidia's investment aims to expand the ecosystem for its hardware and software, benefiting from increased demand for accelerated computing in drug design.

Sep 23, 2026

This article analyzes Johnson & Johnson (JNJ) and AbbVie (ABBV) in the 2H 2026 healthcare dividend roundup, highlighting JNJ's justified premium over ABBV due to its stronger balance sheet, lower payout ratio, and superior capital allocation flexibility. The author argues that JNJ's defensive profile is bolstered by its conservative financials and recent legal resolution, despite trading at a higher P/E multiple. The analysis suggests JNJ is a more compelling investment for long-term growth and income investors.

Sep 23, 2026

AbbVie's drug Rinvoq has received its 11th European Union approval, this time for active polyarticular juvenile idiopathic arthritis in patients aged two and older. This expansion is crucial for AbbVie as it aims to replace lost Humira sales, with Rinvoq's sales increasing significantly in the first half of 2026. The approval, while not a major stock-moving event, contributes to Rinvoq's growth story as the company builds its immunology portfolio.

Sep 23, 2026

This article compares two healthcare ETFs: Invesco's Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Healthcare ETF (IYH). IBBQ offers a more concentrated, biotech-focused, high-risk, high-reward investment with a lower expense ratio and higher one-year return, while IYH provides broader exposure to the entire healthcare sector, higher dividend yield, and more stability for conservative investors. The choice between the two depends on an investor's risk tolerance and investment goals.

Sep 22, 2026

AbbVie's drug Rinvoq received EU approval for treating polyarticular juvenile idiopathic arthritis in children as young as two, marking its eleventh indication in Europe. While this approval adds a smaller patient group and less immediate revenue compared to adult indications, it secures a longer treatment duration per patient, which is crucial for AbbVie's strategy to offset the decline of Humira sales. Despite strong trial results and a new weight-dosed oral solution, the small patient population, lower pediatric revenue, and existing safety warnings for JAK inhibitors like Rinvoq mean Skyrizi continues to be the primary driver in AbbVie's post-Humira transition.

Sep 22, 2026

AbbVie's drug Rinvoq has received its 11th EU approval for treating active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged two years and older. This approval is based on positive results from the SELECT-YOUTH study and further solidifies Rinvoq's role as a significant growth driver for AbbVie, with sales expected to reach around $10.2 billion in 2026. Separately, AbbVie also announced a collaboration with Iambic to advance AI-driven drug discovery for small-molecule therapies.

Sep 22, 2026

Johnson & Johnson (JNJ) stock has outperformed several rivals with higher revenue growth, such as Eli Lilly, over the past twelve months. This surprising performance is attributed to investor confidence in JNJ's growth prospects once the declining sales of its immunology drug STELARA are factored out, as other key drugs like TREMFYA and DARZALEX are experiencing strong growth. While the MedTech segment has shown slower growth, the market is betting on new medicines to drive future revenue, despite some headwinds like Abiomed's sales decline and an extra week in the 2026 calendar muddying revenue targets.

Sep 22, 2026

AbbVie (NYSE:ABBV) is a relevant stock to watch today as defensive healthcare demand supports the sector. The market is selective, focusing on business quality and execution amid varied macroeconomic factors like interest rates, energy prices, and technology interest. The company's business model durability and customer demand signals will be key in understanding its performance within the current market environment.

Sep 22, 2026

This article compares AbbVie and Pfizer as dividend investments, highlighting AbbVie's status as a Dividend King with over 50 years of dividend increases and strong cash flow, even after Humira's exclusivity loss. Pfizer, despite facing declining demand post-COVID vaccine, is showing recovery with strategic investments and an 18% operational revenue increase, maintaining a stable dividend yield. The analysis suggests AbbVie offers robust financial strength and consistent shareholder returns, while Pfizer presents a recovery story with a higher dividend yield but potential market concerns.

Sep 22, 2026

AbbVie (NYSE:ABBV) has received European Commission approval for Rinvoq (upadacitinib) to treat active polyarticular juvenile idiopathic arthritis in children aged two years and older. This approval expands Rinvoq's existing indications in the EU, offering a new treatment option for pediatric patients who have not responded to other disease-modifying antirheumatic drugs. The drug is already approved for several inflammatory conditions in the region.

Sep 22, 2026

AbbVie announced that the European Commission has approved RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older. This approval is based on data from the SELECT-YOUTH study and adult rheumatoid arthritis patients, offering a new oral solution for children who have responded inadequately to other treatments. The drug aims to improve pain and physical function and potentially lead to remission in pJIA, a debilitating disease affecting many children in Europe.

Sep 22, 2026

AbbVie Inc. (ABBV) demonstrates strong market confidence, trading near its 52-week high with a market capitalization of $466.45 billion and positive momentum indicators. While its high dividend payout ratio of 190.40% raises some concerns about sustainability, the company's robust free cash flow and diverse product portfolio support its financial health. Analysts largely favor ABBV, projecting a 5.55% upside potential, driven by its innovative pipeline in autoimmune diseases, oncology, and neuroscience.

Sep 21, 2026

AbbVie and Iambic have announced a multi-year collaboration to use Iambic's AI platform for accelerating small molecule drug discovery in immunology, neuroscience, and oncology. The partnership aims to improve the efficiency of identifying new drug candidates by leveraging Iambic's molecular superintelligence platform, which includes technologies like Enchant and NeuralPLexer, alongside AbbVie's therapeutic expertise. This collaboration is expected to reduce drug discovery timelines and lead to the development of better medicines for patients.

Sep 20, 2026

Bristol Myers Squibb's stock is gaining bullish attention due to its undervalued status compared to peers, strong growth portfolio, and robust dividend. Despite patent expiration concerns for key drugs, the company's newer therapies and pipeline are expected to drive future revenue, making it an attractive investment with a high margin of safety. There's also speculation about a potential acquisition by AstraZeneca, which could significantly boost its stock.

Sep 18, 2026

As of January 31, 2026, the Schwab S&P 500 Index Fund, part of Schwab Capital Trust, reported total net assets of over $133.7 billion. AbbVie Inc. is the fund's largest equity holding, valued at approximately $886 million. This data provides investors with insight into the fund's significant equity exposures and portfolio allocation.

Sep 18, 2026

AbbVie Inc. has declared a quarterly dividend of $1.73 per share, maintaining its payout for 2026, which translates to an annual yield of around 2.7%. While the current yield is moderate, the article highlights AbbVie's consistent history of dividend growth, increasing its quarterly payout by over 330% since 2013, with the latest increase being 5.5%. The company's strong operating cash flow supports its dividends, but investors should monitor future growth rates and other capital commitments, as the dividend growth has slowed in recent years.

Sep 18, 2026

AbbVie presented new real-world data at Psych Congress 2026 for its drug VRAYLAR (cariprazine), demonstrating its effectiveness in improving depressive symptoms, functioning, and quality of life in adults with major depressive disorder (MDD) and bipolar I (BP-I) depression. These studies, CReW BP-I and ProACt, reinforce that the benefits observed in clinical trials translate to real-world clinical practice, providing confidence for healthcare providers in making individualized treatment decisions. The presentations also included an indirect comparative analysis in MDD, long-term pediatric safety data, and patient preference research, highlighting VRAYLAR's role as an important treatment option for mood disorders.

Sep 18, 2026

This article compares AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) as potential healthcare stock investments for 2026, weighing their financial performance, growth strategies, and risk profiles. While Bristol Myers Squibb appears cheaper based on valuation metrics, AbbVie is recommended due to its successful navigation of patent cliffs and strong immunology and neuroscience pipeline, making it a more predictable choice for patient investors.

Sep 18, 2026

Bank of America Corp DE has made a new investment of $160.51 million in Ball Corporation (NYSE:BALL), acquiring 2,572,217 shares during the second quarter. This move makes Bank of America Corp DE a significant institutional holder with about 0.97% ownership of Ball. Other institutional investors have also adjusted their positions in Ball, which recently announced a quarterly dividend and strong earnings results, with analysts maintaining a "Moderate Buy" consensus rating.

Sep 18, 2026

AbbVie's stock is trading near its 52-week high, largely driven by the strong growth of its drugs SKYRIZI and RINVOQ, while older medicines like HUMIRA are shrinking. The article explores the potential risks if SKYRIZI's growth engine slows down, considering new market rivals, payer negotiations, and patent expirations. It emphasizes that a slowdown would gradually impact the stock, and investors should monitor upcoming catalysts like FDA rulings and quarterly reports.

Sep 17, 2026

AbbVie will present new data from its multiple myeloma research portfolio, including Phase 3 CERVINO study results for etentamig, at the 23rd International Myeloma Society (IMS) Annual Meeting in September 2026. The CERVINO study showed etentamig met its dual primary endpoints of objective response rate and progression-free survival in relapsed/refractory multiple myeloma. Additional presentations will cover other investigational assets like ABBV-2001 and surzetoclax, highlighting AbbVie's strategy to develop diverse and complementary treatments for the complex disease.

Sep 17, 2026

Auxier Asset Management highlighted Merck & Co. (MRK) in its Q2 2026 investor letter, noting the company's successful execution with new products like Winrevair, Welireg, and Capvaxive. These new offerings are helping to reduce Merck's dependence on its blockbuster cancer drug Keytruda. Despite strong performance, Auxier Asset Management suggests other AI stocks might offer greater upside potential with less downside risk.

Sep 17, 2026

William Blair initiated coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with an Outperform rating, anticipating its lead cancer drug, azenosertib, could achieve $1.3 billion in peak sales. The drug, an oral WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer, is expected to launch in 2028 with potential for accelerated approval based on positive Phase 2 DENALI trial results. Despite promising early data and improved tolerability over competitors, the company faces clinical, competitive, and funding risks.

Sep 15, 2026

Wolfe Research upgraded Biogen (BIIB) and AbbVie (ABBV) to Outperform, assigning both $300 price targets due to undervalued pipelines and low valuations. Biogen's upgrade is driven by late-stage clinical programs and strategic M&A, while AbbVie's is based on strong patent positions and robust cash generation, particularly with its immunology drugs. The report contrasts their risk profiles, with Biogen offering higher upside potential linked to clinical catalysts and AbbVie presenting a more stable, longevity-focused investment.

Sep 15, 2026

AbbVie has partnered with the PGA TOUR to become its official pharmaceutical sponsor and the sponsor of the 2026 Presidents Cup. This partnership introduces "Birdies for Brain Health," a multi-year campaign aimed at raising awareness and support for individuals with brain health conditions and their care partners, with initial donations going to six patient advocacy organizations. The campaign will scale in 2027 to include donations for every birdie made at PGA TOUR Signature Events and FedExCup Playoffs, and will feature golf professional Gary Woodland, who has publicly shared his experience recovering from brain surgery.

Sep 15, 2026

AbbVie and BioLabs University of Toronto have announced the opening of applications for the AbbVie Biotech Innovators Award, aimed at supporting early-stage biotechnology companies in Ontario. Two winning companies will receive a year of free laboratory space, equipment access, and mentorship from AbbVie's experts. This initiative seeks to accelerate the development of innovative healthcare solutions and bolster Ontario's life sciences sector.

Sep 14, 2026

REGENXBIO Inc. announced its participation in two upcoming investor conferences: the Baird 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Both events will feature fireside chats held in New York, NY on September 15 and September 16, 2026, respectively. Webcasts of these events will be available on REGENXBIO's investor relations website.